pfizer inc pfe said wednesday that the food and drug administration and the european medicines agency accepted the new drug application for its ulcerative colitis treatment candidate the fda is expected to make a decision whether to approve etrasimod in the second half of next year pfizer recently told investors it expects the drug to generate up to 2 billion in peak sales the companys stock is down 131 this year while the broader sp 500 spx had declined 198  eonventional biologic or janus kinase jak inhibitor therapy both randomized doubleblind placebocontrolled studies achieved all primary and key secondary endpoints with a safety profile consistent with previous studies fdsupfactsetdoc20viewer20singleexpandpd7qt5floatwindowtrue